Author

Gabriela Muricy 1

1 Takeda Pharmaceuticals International. Inc., São Paulo, Brazil

COST PER CLINICAL OUTCOMES WITH VEDOLIZUMAB FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN BRAZIL

Tassia Decimoni, Gabriela Muricy, Haridarshan Patel, Dirk Demuth

Item 1 - 1 / 1
1